

Accepted Manuscript

Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers



Martin Jönsson, Gill Munding, Michael Sumner

PII: S0928-0987(18)30280-X

DOI: doi:[10.1016/j.ejps.2018.06.024](https://doi.org/10.1016/j.ejps.2018.06.024)

Reference: PHASCI 4566

To appear in: *European Journal of Pharmaceutical Sciences*

Received date: 5 February 2018

Revised date: 19 June 2018

Accepted date: 20 June 2018

Please cite this article as: Martin Jönsson, Gill Munding, Michael Sumner , Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. Phasci (2018), doi:[10.1016/j.ejps.2018.06.024](https://doi.org/10.1016/j.ejps.2018.06.024)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers

Martin Jönsson^a, Gill Munding^b, Michael Sumner^c

^a Orexo AB, Rapskatan 7E, SE-754 50, Uppsala, Sweden. Email: Martin.Jonsson@orexo.com

^b Mundipharma Research Limited, Cambridge Science Park, Milton Road, Cambridge, CB4 0AB, UK. Email: Gill.Munding@mundipharma-rd.eu

^c Orexo US, Inc., 150 Headquarters Plaza, East Tower, Morristown, New Jersey, 07960 US. Email: Michael.Sumner@orexo.com

Corresponding author:

Name and address: Gill Munding, Mundipharma Research Limited, Cambridge Science Park, Milton Road, Cambridge, CB4 0AB

E-mail: Gill.Munding@mundipharma-rd.eu

Tel: +44 (0) 1223 424900

Download English Version:

<https://daneshyari.com/en/article/8510874>

Download Persian Version:

<https://daneshyari.com/article/8510874>

[Daneshyari.com](https://daneshyari.com)